Fizzah Choudry
YOU?
Author Swipe
View article: Cost-Effectiveness of Early Discharge (<48 Hours) for Low-Risk Patients Following PPCI for STEMI
Cost-Effectiveness of Early Discharge (<48 Hours) for Low-Risk Patients Following PPCI for STEMI Open
Selected low-risk patients can be discharged securely and safely following successful primary percutaneous coronary intervention using a pathway that is reinforced by a formal, multidisciplinary virtual follow-up program, enabling improvem…
View article: 63 Prospective observational study of the use of simulation for the assessment of competence for percutaneous coronary intervention
63 Prospective observational study of the use of simulation for the assessment of competence for percutaneous coronary intervention Open
Introduction Current interventional cardiology training in the United Kingdom is based on direct observed procedures and maintenance of a logbook of cases performed by each interventional trainee. Whilst this may provide some evidence of a…
View article: The safety of deferred coronary angiography in COVID-19 patients with acute coronary syndrome: the Barts COVID recovered pathway.
The safety of deferred coronary angiography in COVID-19 patients with acute coronary syndrome: the Barts COVID recovered pathway. Open
This study demonstrates the safety and effectiveness of deferred coronary angiography on a COVID-Recovered pathway after a period of medical management for patients presenting with NSTEMI and concurrent COVID-19 infection. There was no adv…
View article: An exploration of the early discharge approach for low-risk STEMI patients following primary percutaneous coronary intervention.
An exploration of the early discharge approach for low-risk STEMI patients following primary percutaneous coronary intervention. Open
Recently, there has been growing interest in the early discharge strategy for low-risk patients who have undergone primary percutaneous coronary intervention (PCI) to treat ST-segment elevation myocardial infarction (STEMI). So far finding…
View article: Five‐year follow‐up of intracoronary autologous cell therapy in acute myocardial infarction: the REGENERATE‐AMI trial
Five‐year follow‐up of intracoronary autologous cell therapy in acute myocardial infarction: the REGENERATE‐AMI trial Open
Aims The long‐term outcomes of the intracoronary delivery of autologous bone marrow‐derived cells (BMCs) after acute myocardial infarction are not well established. Following the promising 1 year results of the REGENERATE‐AMI trial (despit…
View article: Transcriptional characterization of human megakaryocyte polyploidization and lineage commitment
Transcriptional characterization of human megakaryocyte polyploidization and lineage commitment Open
Background: Megakaryocytes (MKs) originate from cells immuno‐phenotypically indistinguishable from hematopoietic stem cells (HSCs), bypassing intermediate progenitors. They mature within the adult bone marrow and release platelets into the…
View article: The impact of the COVID-19 pandemic on the delivery of primary percutaneous coronary intervention in STEMI.
The impact of the COVID-19 pandemic on the delivery of primary percutaneous coronary intervention in STEMI. Open
Enhanced infection prevention and control procedures considering the COVID-19 pandemic did not impede the delivery of pPCI in our single centre cohort. The public health impact of the pandemic has been demonstrated with times being signifi…
View article: Therapeutic Implications of COVID-19 for the Interventional Cardiologist
Therapeutic Implications of COVID-19 for the Interventional Cardiologist Open
Although COVID-19 is viewed primarily as a respiratory disease, cardiovascular risk factors and disease are prevalent among infected patients and are associated with worse outcomes. In addition, among multiple extra-pulmonary manifestation…
View article: Single cell transcriptional characterization of human megakaryocyte lineage commitment and maturation
Single cell transcriptional characterization of human megakaryocyte lineage commitment and maturation Open
In the current understanding of adult bone marrow hematopoiesis, megakaryocytes (MKs) originate from cells immuno-phenotypically indistinguishable from hematopoietic stem cells (HSCs), bypassing intermediate progenitors. Here, we use singl…
View article: Thrombus Embolisation: Prevention is Better than Cure
Thrombus Embolisation: Prevention is Better than Cure Open
Thrombus embolisation complicating primary percutaneous coronary intervention in ST-elevation myocardial infarction is associated with an increase in adverse outcomes. However, there are currently no proven recommendations for intervention…
View article: Novel insights into megakaryopoiesis, thrombopoiesis and acute coronary thrombosis: transcriptome profiling of the haematopoietic stem cell, megakaryocyte and platelet
Novel insights into megakaryopoiesis, thrombopoiesis and acute coronary thrombosis: transcriptome profiling of the haematopoietic stem cell, megakaryocyte and platelet Open
The aim of this project was to investigate the transcriptome of human haematopoietic stem cells (HSCs), megakaryocytes and platelets to gain insights into steady state and accelerated thrombopoiesis that occurs in states of haemostatic dem…
View article: Potency of Human Cardiosphere-Derived Cells from Patients with Ischemic Heart Disease Is Associated with Robust Vascular Supportive Ability
Potency of Human Cardiosphere-Derived Cells from Patients with Ischemic Heart Disease Is Associated with Robust Vascular Supportive Ability Open
Cardiosphere-derived cell (CDC) infusion into damaged myocardium has shown some reparative effect; this could be improved by better selection of patients and cell subtype. CDCs isolated from patients with ischemic heart disease are able to…
View article: An exploratory randomized control study of combination cytokine and adult autologous bone marrow progenitor cell administration in patients with ischaemic cardiomyopathy: the <scp>REGENERATE‐IHD</scp> clinical trial
An exploratory randomized control study of combination cytokine and adult autologous bone marrow progenitor cell administration in patients with ischaemic cardiomyopathy: the <span>REGENERATE‐IHD</span> clinical trial Open
Aims The effect of combined cytokine and cell therapy in ischaemic cardiomyopathy is unknown. Meta‐analyses suggest improved cardiac function with cell therapy. The optimal cell delivery route remains unclear. We investigated whether granu…